Somatic activating mutations of the KRAS gene are the most observed in NSCLC, especially in lung adenocarcinoma (about 20–30%), and less frequently in in squamous cell carcinoma (about 5%) [141]. Here, KRAS is linked to lung adenocarcinoma.